ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK amps up AI with Insilico pact

by Lisa M. Jarvis
August 28, 2017 | APPEARED IN VOLUME 95, ISSUE 34

Aiming to bolster its abilities in the hot area of artificial intelligence research, GlaxoSmithKline will collaborate with Insilico Medicine. Under the deal, which follows a pilot pact, GSK will use technology from Baltimore-based Insilico to look for novel biological targets and pathways. Meanwhile, GSK has lost its head of drug discovery and preclinical development, Ian Churcher, to BenevolentBio, a subsidiary of another AI firm, BenevolentAI.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment